logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9724370 B1

PDFFull Text
Date of Patent:
Aug. 08, 2017

Filed:

Sep. 08, 2015

Amniotic membrane preparations and purified compositions and therapy for scar reversal and inhibition

Applicant:

Tissuetech, Inc., Doral, FL (US);

Inventors:

Scheffer Tseng, Pinecrest, FL (US);

Hua He, Miami, FL (US);

Wei Li, Shenzhen, CN;

Assignee:

TISSUETECH, INC., Miami, FL (US);

Attorney:

Wilson Sonsini Goodrich & Rosati

Primary Examiner:

Taeyoon Kim

Int. Cl.
CPC ...
A61K 35/50 (2015.01); A61K 9/00 (2006.01); A61K 31/738 (2006.01); A61L 15/40 (2006.01); C07K 14/47 (2006.01); A61K 38/17 (2006.01); A61K 35/48 (2015.01); A61K 38/39 (2006.01); A61K 38/48 (2006.01); C07K 14/78 (2006.01); C07K 14/81 (2006.01); A61K 9/06 (2006.01); A61K 9/08 (2006.01); A61L 15/44 (2006.01);
U.S. Cl.
CPC ...
A61K 35/50 (2013.01); A61K 9/0014 (2013.01); A61K 9/0048 (2013.01); A61K 9/0053 (2013.01); A61K 9/06 (2013.01); A61K 9/08 (2013.01); A61K 31/738 (2013.01); A61K 35/48 (2013.01); A61K 38/1709 (2013.01); A61K 38/39 (2013.01); A61K 38/4886 (2013.01); A61L 15/40 (2013.01); A61L 15/44 (2013.01); C07K 14/4702 (2013.01); C07K 14/4718 (2013.01); C07K 14/78 (2013.01); C07K 14/8114 (2013.01); A61L 2300/412 (2013.01); A61L 2300/64 (2013.01);
Abstract

Compositions having a combination of specific biological components have been found to exert a number of useful effects in mammalian cells, including modulating TGF β signaling, apoptosis, and proliferation of mammalian cells, as well as decreasing inflammation in mice. These components can be obtained commercially, or can be prepared from biological tissues such as placental tissues. Placental amniotic membrane (AM) preparations described herein include AM pieces, AM extracts, AM jelly, AM stroma, and mixtures of these compositions with additional components. The compositions can be used to treat various diseases, such as wound healing, inflammation and angiogenesis-related diseases.

Find Patent Forward Citations

Loading…